NF-κB-IN-15

NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) [1].

Product Specifications

UNSPSC

12352005

Target

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nf-κb-in-15.html

Solubility

10 mM in DMSO

Smiles

CC1=C(C)C=CC=C1N2CCN(C([C@H](CC3=CC(OC)=C(O)C(OC)=C3)[C@@H](C(N4CCN(C5=CC=CC(C)=C5C)CC4)=O)CC6=CC(OC)=C(O)C(OC)=C6)=O)CC2

Molecular Formula

C46H58N4O8

Molecular Weight

794.97

References & Citations

[1]Zhang J, et al. Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury. Eur J Med Chem. 2024 Feb 20;268:116272.